Tibotec's novel TMC207 shows promise in multidrug-resistant TB
This article was originally published in Scrip
Executive Summary
Tibotec's (J&J's) investigational antimycobacterial drug TMC207 has demonstrated efficacy in 48% of patients with multidrug-resistant tuberculosis in a Phase II study. The findings were published in the NEJM online on June 4th.